Technical Analysis for AVXL - Anavex Life Sciences Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.22% | |
| Pocket Pivot | Bullish Swing Setup | 0.22% | |
| Stochastic Reached Overbought | Strength | 0.22% |
| Alert | Time |
|---|---|
| Down 1% | about 8 hours ago |
| Rose Above Previous Day's High | about 8 hours ago |
| Up 3% | about 8 hours ago |
| Up 2% | about 8 hours ago |
| Up 1% | about 8 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/09/2024
Anavex Life Sciences Corp. Description
Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer's disease. The company's product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Pain Neuroscience Alzheimer's Disease Chemical Compounds Lewy Body Dementia Central Nervous System Disease Treatment Of Alzheimer's Disease Piperidines Neuroprotection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.31 |
| 52 Week Low | 3.25 |
| Average Volume | 1,303,130 |
| 200-Day Moving Average | 6.22 |
| 50-Day Moving Average | 4.36 |
| 20-Day Moving Average | 3.82 |
| 10-Day Moving Average | 4.02 |
| Average True Range | 0.26 |
| RSI (14) | 63.77 |
| ADX | 21.78 |
| +DI | 32.55 |
| -DI | 15.22 |
| Chandelier Exit (Long, 3 ATRs) | 3.88 |
| Chandelier Exit (Short, 3 ATRs) | 4.04 |
| Upper Bollinger Bands | 4.42 |
| Lower Bollinger Band | 3.22 |
| Percent B (%b) | 1.07 |
| BandWidth | 31.56 |
| MACD Line | 0.00 |
| MACD Signal Line | -0.14 |
| MACD Histogram | 0.1357 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.85 | ||||
| Resistance 3 (R3) | 4.87 | 4.77 | 4.79 | ||
| Resistance 2 (R2) | 4.77 | 4.68 | 4.76 | 4.77 | |
| Resistance 1 (R1) | 4.64 | 4.62 | 4.59 | 4.62 | 4.75 |
| Pivot Point | 4.54 | 4.54 | 4.51 | 4.53 | 4.54 |
| Support 1 (S1) | 4.40 | 4.45 | 4.35 | 4.38 | 4.25 |
| Support 2 (S2) | 4.30 | 4.39 | 4.29 | 4.23 | |
| Support 3 (S3) | 4.17 | 4.30 | 4.21 | ||
| Support 4 (S4) | 4.15 |
